rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination.Data from a large phase 2 randomized double-blind clinical trial (PREVAC) were used to evaluate waning of anti-Ebola virus (EBOV) glycoprotein (GP1,2) antibody concentrations after rVSVΔG-ZEBOV-GP or Ad26.ZEBOV, MVA-BN-Filo vaccination with linear mixed-effect regression models.After a post-vaccination peak, each vaccination strategy was associated with a decrease of anti-EBOV GP1,2 antibody concentrations with distinct kinetics, highlighting a less-rapid decline in antibody levels after vaccination by rVSVΔG-ZEBOV-GP. One year after administration of the vaccine, antibody concentrations were higher in children compared to adults for both vaccines, although with different effect sizes: 1.74-fold higher concentrations (95% confidence interval [CI] [1.48; 2.02]) for children 12-17 years old to 3.10-fold higher concentrations (95% CI [2.58; 3.69]) for those 1-4 years old compared to adults for Ad26.ZEBOV, MVA-BN-Filo versus 1.36-fold (95% CI [1.12; 1.61]) to 1.41-fold (95% CI [1.21; 1.62]) higher at month 12 higher than these values for adults, with relatively small changes from one age category of children to another for rVSVΔG-ZEBOV-GP. Antibody concentrations also differed according to geographical location, pre-vaccination antibody concentration, and sex.In combination with knowledge on memory response, characterization of the major determinants of immune response durability of both vaccinations may guide future EVD control protocols.Trial registration: ClinicalTrials.gov identifier: NCT02876328..

中文翻译：

---

rVSVΔG-ZEBOV-GP 和 Ad26.ZEBOV、MVA-BN-Filo 埃博拉病毒病疫苗后 IgG 抗体反应减弱的评估：PREVAC 随机试验的建模研究。


rVSVΔG-ZEBOV-GP 和 Ad26.ZEBOV、MVA-BN-Filo 是 WHO 资格预审的埃博拉病毒病 （EVD） 疫苗接种方案。与测量长期临床保护相关的挑战需要评估疫苗接种后的免疫反应动力学。来自大型 2 期随机双盲临床试验 （PREVAC） 的数据用于评估 rVSVΔG-ZEBOV-GP 或 Ad26.ZEBOV、MVA-BN-Filo 疫苗接种后抗埃博拉病毒 （EBOV） 糖蛋白 （GP1,2） 抗体浓度的减弱线性混合效应回归模型。在疫苗接种后达到峰值后，每种疫苗接种策略都与具有不同动力学的抗 EBOV GP1,2 抗体浓度降低相关，突出了 rVSVΔG-ZEBOV-GP 疫苗接种后抗体水平下降的速度较慢。接种疫苗一年后，与成人相比，两种疫苗的儿童抗体浓度更高，尽管效应大小不同：12-17 岁儿童的浓度高 1.74 倍（95% 置信区间 [CI] [1.48;2.02]），与 Ad26.ZEBOV 的成人相比，1-4 岁儿童的浓度高 3.10 倍（95% CI [2.58;3.69]）， 在第12个月时，MVA-BN-Filo与1.36倍（95% CI [1.12;1.61]）至1.41倍（95% CI [1.21;1.62]）比成人的这些值高，rVSVΔG-ZEBOV-GP 从一个年龄组到另一个年龄组儿童的变化相对较小。抗体浓度也因地理位置、疫苗接种前抗体浓度和性别而异。结合记忆反应知识，两种疫苗接种免疫反应持久性的主要决定因素的特征可能指导未来的 EVD 控制方案。试用注册：ClinicalTrials.gov 标识符：NCT02876328..